Does Bupropion contain caffeine?(+3 Factors)
By
Dr Milena Locci de Oliveira (PhD)
Author bio
Dr Milena Locci de Oliveira is a Pharmacist and Doctor of Philosophy in Sciences from the University of São Paulo (USP). She has experience in microbiology, analytical toxicology, and clinical pharmacokinetics. She writes and reviews content on these topics.
Dr Milena’s Highlights:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration in the areas of Pharmacometrics and Population Pharmacokinetics, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
“Science can be translated, and it is essential that everyone has access to quality information to make informed decisions” – Dr Milena Oliveira, PhD.
Professional Experience:
With a decade-long career as a researcher, Dr Milena has amassed extensive experience in conducting research projects in microbiology, analytical toxicology, and clinical pharmacokinetics.
Her expertise also extends to the preparation of technical and scientific reports, literature reviews, data analysis, and scientific communication, both oral and written.
Dr Milena has served as a Clinical Pharmacist, providing expert supervision and guidance to teams during the challenging times of the COVID-19 pandemic, particularly in the ICUs of two reference hospitals for patient hospitalization.
In her most recent role, Dr Milena worked on the implementation of the deliberatives of the São Paulo State Government Pharmaceutical Assistance Coordination. These decisions were aimed at ensuring medication access within the Unified Health System.
A widely multidisciplinary background enabled Dr Milena to become a professional capable of integrating scientific knowledge into private initiatives, education, and healthcare, delivering consistent services in patient safety and population health.
Professional Memberships & Affiliations:
Dr Milena Oliveira is a member of the Regional Council of Pharmacy of the State of São Paulo, Brazil.
Education:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
Relevant Published Work & Citations:
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis. Nov 2020. 191:113-124.
Abstracts. CPT: Pharmacometrics & Systems Pharmacology. 2020 Nov; 9 (S1).
Pippa LF, Oliveira ML de, Rocha A, de Andrade JM, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis. 2020 Jun 5; 185:113-231.
Godoy ALPC, De Jesus C, De Oliveira ML, Rocha A, Pereira MPM, Larangeira DF, Lanchote VL, Barrouin-Melo SM. Determination of Allopurinol and Oxypurinol in Dogs Plasma by High-Performance Liquid Chromatography with an Ultraviolet Detector: Application for Pharmacokinetic Studies. J Chromatogr Sep Tech. 2017; 8 (4).
Clímaco EC, Oliveira ML de, Pitondo-Silva A, Oliveira MG, Medeiros M, Lincopan N, et al. Clonal complexes 104, 109 and 113 playing a major role in the dissemination of OXA-carbapenemase-producing Acinetobacter baumannii in Southeast Brazil. Infection, Genetics and Evolution. 2013 Oct;19:127–33.
Conference Papers:
Oliveira, M. L.; NARDOTTO, G. H. B.; PIPPA, L. F.; ROCHA, A.; SIMOES, B. P.; LANCHOTE, V. L. . Daunorubicin metabolism and urinary excretion in patients with acute myeloid leukemia. In: 84th Annual Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) and the 20th Annual Meeting of the Association of the Clinical Pharmacology Germany (VKliPha), 2018, Göttingen. Naunyn-Schmiedeberg’s Arch Pharmacol, 2018. v. 391. p. S76-S76.
Oliveira, M. L.; NARDOTTO, G. H. B. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . The low contribution of urinary excretion in the elimination of daunorubicin and its metabolite daunorubicinol in patients with acute myeloid leukemia. In: 49th Brazilian Congress of Pharmacology and Experimental Therapeutics., 2017, Ribeirão Preto. Livro de Resumos, 2017. p. 64-64.
Oliveira, M. L.; PIPPA, L. F. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . Quantification of daunorubicin and its metabolite daunorubicinol in human plasma by LC-MS/MS. In: I International Meeting of Environmental Health and Toxicology (IMEHTOX), 2016, Ribeirão Preto. Livro de Resumos, 2016.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. . PFGE typing of Carbapenem-Resistant Acinetobacter baumannii isolated from different University Hospitals. In: V International Postgraduate and Research Symposium, 2012.
Clímaco, E.C. ; SILVA, A. P. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. Relação clonal entre linhagens de Acinetobacter baumannii produtoras de carbapenemases da família OXA em quatro hospitais no Brasil. In: XXI Latin American Congress of Microbiology, 2012, Santos. XXI Latin American Congress of Microbiology, 2012.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Darini A.L.C. . Dissemintion of OXA carbapenemases genes in carbapenem-resistant Acinetobacter baumannii in University Hospital of Juiz de Fora, MG. In: 8th CIFARP – International Congress of Pharmaceutical Sciences, 2011, Ribeirão Preto.
Clímaco, E.C. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Darini A.L.C. . Avaliação do sequenciamento parcial do gene rpoB e de seus flanqueadores para identificação de espécies de Acinetobacter na rotina laroratorial. In: 2° International Symposium on Clinical Microbiology, 2010, Florianópolis.
You can view some of Dr Milena’s work below and links to her professional profile.
Linkedin: https://www.linkedin.com/in/dra-milena-locci-de-oliveira-28986042/?locale=en_US
ResearchGate: https://www.researchgate.net/profile/Milena-Oliveira-6
Escavador: https://www.escavador.com/sobre/5394254/milena-locci-de-oliveira
Lattes: https://buscatextual.cnpq.br/buscatextual/busca.do
Scopus: https://www.scopus.com/authid/detail.uri?authorId=57199779361
Scholar: https://scholar.google.com/citations?view_op=list_works&hl=pt-BR&user=1YUBDIQAAAAJ
In this article we will discuss Does Bupropion contain caffeine. What are the composition and characteristics of Bupropion? its pharmacological profile and active ingredients, experts’ opinions, its interaction with caffeine and Why should you avoid using Caffeine and Bupropion together.
Does Bupropion contain Caffeine?
No, Bupropion doesn’t contain caffeine. Bupropion is a medication that is commonly used to treat depression and help with smoking cessation. It is not related to caffeine and does not contain caffeine as an active ingredient.
What are the composition and characteristics of Bupropion?
Bupropion also known by its brand name Wellbutrin and Zyban, is a compound with a distinct chemical structure. It is classified as an aminoketone and belongs to the class of drugs known as atypical antidepressants.
Bupropion does not contain caffeine as one of its ingredients the active ingredient in bpropion is bupropion hydrochloride. Caffeine and bupropion are different substances with different properties and applications.
It is primarily prescribed as an antidepressant to treat major depressive disorder. Unlike other antidepressants, it works by affecting norepinephrine and dopamine levels in the brain, rather than serotonin.
It is also prescribed as an aid for smoking cessation.
What is Bupropion’s pharmacological profile?
Bupropion, a medication by its brand name Wellbutrin has a distinct pharmacological profile:
Pharmacological Profile
- Bupropion is an atypical antidepressant that enhances norepinephrine and dopamine levels in the brain by inhibiting their reuptake. This unique mechanism makes it effective in treating depression, and social anxiety and assisting in smoking cessation.
- Bupropion produces stimulant effects that enhance alertness and energy, unrelated to caffeine.
- Compared to other antidepressants, bupropion has a lower risk of causing sexual dysfunction.
- Bupropion is generally associated with minimal impact on sleep patterns.
What is involved in the analysis of Bupropion’s manufacturing process?
The analysis of bupropion’s labelling and manufacturing processes involves several key aspects:
- Labelling Information
- Regulatory compliance
- Quality Control
- Batch Validation
- Packaging and Labelling Compliance
- Pharmacovigilance
- Manufacturing Facilities
What are the expert opinions regarding caffeine in Bupropion?
Experts’ opinions and research are consistent in confirming that bupropion does not contain caffeine as one of its ingredients. The absence of caffeine is a well-known fact based on both clinical and pharmacological evidence. here are more details :
- Bupropion works by inhibiting the reuptake of norepinephrine and dopamine in the brain. There is no involvement of caffeine in this process.
- Bupropion undergoes clinical trials and studies to assess its safety and efficacy. At this point in the trials, it is evident that there is no caffeine present in Bupropion (2).
- Medical professionals, pharmacologists and researchers concur that bupropion and caffeine are two different substances.
What are the common sources of misconceptions about Bupropion?
Common sources of confusion about Bupropion include its similar-sounding names, incomplete and accurate information from medical sources, a general lack of awareness, media portrayals, and variability in the formulation. To address this misconception, it is crucial to consult healthcare professionals and reliable sources for accurate information about Bupropion.
Do Bupropion and Caffeine interact?
Bupropion and caffeine can indeed interact, possibly causing negative consequences and increased excitement. The degree of the interaction can however differ from person to person. Caffeine and Bupropion can have several negative consequences including elevated anxiety, disturbed sleep, changes in blood pressure and heart rate, especially with patients with specific medical conditions or excessive caffeine intake. In such cases, healthcare providers reduce caffeine consumption, adjust the dosage regime of bupropion, or may consider other treatment options.
Why should you avoid using Bupropion and Caffeine together?
Here are the key points for avoiding taking Buropion and Caffeine together (3):
- It can lead to heightened stimulation and alertness.
- It can elevate your blood pressure.
- It can lead to sleep disturbances.
- It can cause heartburn.
- It can raise the potential risk of seizures and anxiety.
Conclusion
In conclusion, the Bupropion does not contain caffeine. However, using Bupropion and Caffeine together can result in heightened stimulation, which can lead to difficulties such as restlessness and insomnia. Therefore, it is recommended to consult your healthcare provider before taking any medication.
Was this helpful?
References
1.-
Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert review of neurotherapeutics. 2006 Sep 1;6(9):1249-65. Avaialble from: https://www.tandfonline.com/doi/abs/10.1586/14737175.6.9.1249
2.-
Yamazaki T, Desai A, Goldwater R, Han D, Howieson C, Akhtar S, Kowalski D, Lademacher C, Pearlman H, Rammelsberg D, Townsend R. Pharmacokinetic effects of isavuconazole coadministration with the cytochrome P450 enzyme substrates bupropion, repaglinide, caffeine, dextromethorphan, and methadone in healthy subjects. Clinical pharmacology in drug development. 2017 Jan;6(1):54-65. Available from: https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/cpdd.281
3.-
Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Additives & Contaminants. 2003 Jan 1;20(1):1-30.Availabe from: https://www.tandfonline.com/doi/abs/10.1080/0265203021000007840
Find a supportive therapist who can help with Depression.
Discover the convenience of BetterHelp, an online therapy platform connecting you with licensed and accredited therapists specialized in addressing issues such as depression, anxiety, relationships, and more. Complete the assessment and find your ideal therapist within just 48 hours.
AskYourPharm is user-supported. We may earn a commission if you sign up for BetterHelp’s services after clicking through from this site
